Results of a Dual-Site Study Involving the Non-Invasive vMap System™ During SAbR Published In Heart Rhythm O2

Vektor Medical, Inc., a private company founded to develop the next-generation in arrhythmia mapping systems, today announced the publication of results of a dual-site study involving its non-invasive vMap™ system during stereotactic ablative radiotherapy (SAbR), in the peer-reviewed journal, Heart Rhythm O2.

The prospective study, led by Dr. Gordon Ho, an Assistant Professor of Medicine and Board-Certified cardiac electrophysiologist from the University of California San Diego, utilized a new non-invasive workflow involving vMap™. The paper described vMap’s role in facilitating arrhythmia “target planning via 3D visualization of [ventricular tachycardia (VT)] exit sites with precision appropriate for non-invasive VT ablation.” Additionally, unlike other workflows which require the use of a mapping vest or concurrent CT scan, the vMap™ workflow requires “only the digital 12-lead ECG data of the ventricular arrhythmia.”

Vektor Medical'S Vmap™ Mapping System Reported As Feasible And Effective As Part Of A Non-Invasive Workflow For Arrhythmia Management When Using Stereotactic Ablative Radiotherapy

“SAbR is an emerging therapy that is showing great potential for treating refractory VT, however the current workflow is complicated and there are safety concerns for patients with significant cardio-respiratory motion and target sites near the stomach,” stated Dr. Ho. “We were able to show that by incorporating the non-invasive vMap™ into radio-ablation planning that we could safely ablate VT, including in those more challenging cases. Further studies will be needed, but this is an exciting first step to improve safety and efficacy of SAbR therapy.”

In the study, non-invasive mapping using vMap™ was successfully performed in all patients, identifying 4.2 ± 2.3 VT morphologies per patient, with a mean mapping time of 1.1 ± 0.1 minute per VT morphology. A total of 7 distinct VT morphologies had previously been mapped during an invasive electrophysiology study, and vMap™ was able to localize the VT exit within the exact cardiac segment in all 7 instances (100%). The study concluded that the non-invasive workflow, using vMap™’s 12-lead ECG mapping, “may help facilitate the radioablation planning workflow and provide short-term safety and maintaining efficacy during SAbR therapy in patients with advanced structural heart disease and refractory VT.”

vMap™, currently under regulatory review, aims to be the first non-invasive mapping tool that uses only 12-lead ECG data to help physicians rapidly locate cardiac arrhythmia activation sites with precision. Using advanced, proprietary algorithms, the vMap™ System turns ECG data into 2D and 3D cardiac maps of both stable and unstable rhythms in all four chambers of the heart, septum, and outflow tracts. Designed to improve first-pass ablation success and reduce procedure time, the streamlined system empowers physicians to efficiently identify target sites while reducing risks associated with invasive mapping techniques.

“While vMap™ was designed to assist the physician with traditional catheter-based arrhythmia therapy, it is exciting to see the value vMap™ may add to this entirely non-invasive SAbR planning and treatment. It is our goal to redefine arrhythmia mapping for all ablation therapies by providing rapid, non-invasive mapping for efficient and accurate identification of hotspots in all four chambers,” said Mike Monko, CEO of Vektor Medical.

Dr. Ho was recently awarded The Schulman Research Award for his outstanding work in cardiovascular medicine. This study is part of his research into how the use of novel cardiac imaging techniques can improve the accuracy of non-invasive ablation therapy of ventricular arrhythmias.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“It’s exciting to be one of the first two hospitals in Europe to use Stryker’s Mixed Reality Guidance System,” said Professor Berhouet. “I am also pleased to be leading a pilot study to investigate the safety and effectiveness of this new technology, alongside three other centres in France.”
The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company’s prototype to validate stability outside of the lab, and is now miniaturized and wearable.
The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy